Evidence map›Paper›PMID 33658587›Full record

ArticleScientific reports2021

Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.

Emmalyn Chen, Clinton L Cario, Lancelote Leong, Karen Lopez, César P Márquez, Carissa Chu, Patricia S Li, Erica Oropeza, Imelda Tenggara, Janet Cowan and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. Liquid biopsy to personalize treatment for metastatic prostate cancer.American journal of translational research · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 2 countries.

Emmalyn ChenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Clinton L CarioDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Lancelote LeongDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Karen LopezDepartment of Urology, University of California, San Francisco, CA, USA.
César P MárquezDivision of Hematology/Oncology, University of California, San Francisco, CA, USA.
Carissa ChuDepartment of Urology, University of California, San Francisco, CA, USA.
Patricia S LiDepartment of Urology, University of California, San Francisco, CA, USA.
Erica OropezaDepartment of Urology, University of California, San Francisco, CA, USA.
Imelda TenggaraDepartment of Urology, University of California, San Francisco, CA, USA.
Janet CowanDepartment of Urology, University of California, San Francisco, CA, USA.
Jeffry P SimkoDepartment of Urology, University of California, San Francisco, CA, USA.
June M ChanDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Terence FriedlanderDivision of Hematology/Oncology, University of California, San Francisco, CA, USA.
Alexander W WyattVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Rahul AggarwalDivision of Hematology/Oncology, University of California, San Francisco, CA, USA.
Pamela L ParisDepartment of Urology, University of California, San Francisco, CA, USA.
Peter R CarrollDepartment of Urology, University of California, San Francisco, CA, USA.
Felix FengDepartment of Urology, University of California, San Francisco, CA, USA.
John S WitteDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. JWitte@ucsf.edu.
University of California, San Francisco · USUniversity of British Columbia · CA

Funding

Genetic Epidemiology of Prostate Cancer Risk and ProgressionR01CA088164 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAN DEN EEDEN, STEPHEN K., WITTE, JOHN S. · 2000 to 2015
$6.1M
Genome-wide Pleiotropy Scan across Multiple CancersR01CA201358 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRAFF, REBECCA ELIZABETH, SAKODA, LORI · 2016 to 2019
$2.5M
NCI NIH HHS R01 CA088164NCI NIH HHS R01 CA201358NIH HHS R01 CA088164
6 · The paper itself

Abstract

Prostate cancer is the most commonly diagnosed neoplasm in American men. Although existing biomarkers may detect localized prostate cancer, additional strategies are necessary for improving detection and identifying aggressive disease that may require further intervention. One promising, minimally invasive biomarker is cell-free DNA (cfDNA), which consist of short DNA fragments released into circulation by dying or lysed cells that may reflect underlying cancer. Here we investigated whether differences in cfDNA concentration and cfDNA fragment size could improve the sensitivity for detecting more advanced and aggressive prostate cancer. This study included 268 individuals: 34 healthy controls, 112 men with localized prostate cancer who underwent radical prostatectomy (RP), and 122 men with metastatic castration-resistant prostate cancer (mCRPC). Plasma cfDNA concentration and fragment size were quantified with the Qubit 3.0 and the 2100 Bioanalyzer. The potential relationship between cfDNA concentration or fragment size and localized or mCRPC prostate cancer was evaluated with descriptive statistics, logistic regression, and area under the curve analysis with cross-validation. Plasma cfDNA concentrations were elevated in mCRPC patients in comparison to localized disease (OR

Indexed as

AdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorCase-Control StudiesCell-Free Nucleic AcidsHumansKallikreinsLogistic ModelsMaleMiddle AgedProstateProstatectomyProstate-Specific AntigenProstatic NeoplasmsBiomarkers, TumorCell-Free Nucleic AcidsKallikreinsKLK3 protein, humanProstate-Specific Antigen

Identifiers

PMID33658587
PMCPMC7930042
OpenAlexW3135345700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.